Image

Global Chronic Obstructive Pulmonary Disease Market – Industry Trends and Forecast to 2030

Healthcare

Image

Global Chronic Obstructive Pulmonary Disease Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables:
  • No of Figures:

Global Chronic Obstructive Pulmonary Disease Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 19.80 Billion
Diagram Market Size (Forecast Year) USD 30.40 Billion
Diagram CAGR %

Major Markets Players

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • CHIESI Farmaceutici SpA

Global Chronic Obstructive Pulmonary Disease Market, By Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End User (Hospitals, Clinics, Homecare Settings, Others) - Industry Trends and Forecast to 2030.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Analysis and Size

The rise in the cases of COPD among populations across the globe is among the important factor expected to intensify the growth and demand of the chronic obstructive pulmonary disease market. In addition, the rise in the consumption of tobacco among the youth population and the increase in the awareness among the population about the use of the generic drug are also expected to contribute to the growth in the global market over the forecast period. Also, the rise in the expenditure on healthcare is providing facilities in developing countries for chronic obstructive pulmonary disease, and the rise in awareness among people across developing and underdeveloped are also likely to enhance the growth of the market. Furthermore, the increase in the R&D investment by the government and major players is also one of the significant factors expected to fuel the growth of the chronic obstructive pulmonary disease market. 

Data Bridge Market Research analyzes that the global chronic obstructive pulmonary disease market which was USD  19.8 billion in 2022, would rocket up to USD 30.4 billion by 2030, and is expected to undergo a CAGR of 4.4% during the forecast period 2023 to 2030. This indicates the market value. “Chronic Bronchitis” dominates the type segment of the global chronic obstructive pulmonary disease market owing to the surge in the number of people suffering from chronic obstructive pulmonary disease. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.    

Chronic Obstructive Pulmonary Disease Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End User (Hospitals, Clinics, Homecare Settings, Others)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa

Market Players Covered

AstraZeneca (UK), Boehringer Ingelheim International GmbH (Germany), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), CHIESI Farmaceutici SpA (Italy), Sunovion Pharmaceuticals Inc (US), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V. (US), Orion Corporation (Finland), Merck & Co., Inc (US), Grifols, S.A. (Spain), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Vectura Group plc (UK), Pfizer Inc (US), Alkermes (Ireland), Almirall, S.A (Spain), Genentech, Inc (US), Biogen (US), and Astellas Pharma Inc. (Japan), among other.  

Market Opportunities

  • Increase in the number of research and development activities
  • Development of new drugs 

Market Definition

Chronic Obstructive Pulmonary Disease (COPD) is a type of chronic inflammatory lung disease that causes difficulty in airflow from the lungs. Various symptoms of COPD consist of difficulty in breathing, production of mucus, cough and wheezing.

Global Chronic Obstructive Pulmonary Disease Market Dynamics

Drivers

Increasing Awareness and Diagnosis

As medical knowledge and awareness of chronic obstructive pulmonary disease continue to grow, there may be an increase in the diagnosis and recognition of the condition. This can lead to a higher demand for diagnostic tools, treatments, and research related to chronic obstructive pulmonary disease.

Rise in the Cases of Copd

A significant global health issue, chronic obstructive pulmonary disease (COPD), affects a lot of individuals. The need for COPD management is growing as the disease burden grows. Smoking tobacco may increase the risk of COPD. Adult smoking addiction has been on the rise all around the world. Workplace pollution and indoor air pollution are additional risk factors.

Opportunities

Development of innovative therapies and treatment approaches

Most COPD treatments focus on managing symptoms and slowing the progression of the disease. However, there is a significant need for new and innovative therapies that provides better outcomes for patients and improve their quality of life. In recent years, research and development have focused on new COPD treatments, including biologics, gene therapies, and other novel approaches. These therapies potentially address the underlying causes of COPD and provide patients with more effective and targeted treatment options.   

Restraints/Challenges

High cost of treatment:

COPD is a chronic disease that often requires long-term care and specialized treatment, which is expensive. In addition, many COPD patients also have other comorbidities, which further increase healthcare costs. The cost of COPD treatment is a major barrier to access for many patients, particularly in developing countries with high healthcare costs and limited insurance coverage. This leads to underdiagnoses and under treatment of the disease, negatively impacting patient outcomes and quality of life.

Recent Developments

  • In April 2022, GlaxoSmithKline Pharmaceuticals launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients. Trelegy Ellipta is India's first once-daily single-inhaler triple therapy (SITT) for COPD patients.
  • In Feb 2022, Teva announced FDA approval of ArmonAir Digihaler inhalation powder, an inhaled corticosteroid (ICS) delivered via Teva’s Digihaler™ device containing built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma.

Global Chronic Obstructive Pulmonary Disease Market Scope

The global chronic obstructive pulmonary disease market is segmented on the basis of type, treatment type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Treatment Type

  • Drugs
  • Bronchodilator Monotherapy
  • Short-Acting Beta2-Agonists (SABAS)
  • Long-Acting Beta2-Agonists (LABAS)
  • Anti-Cholinergic Agents
  • Anti-Inflammatory Drugs
  • Oral And Inhaled Corticosteroids
  • Anti-Leukotrienes
  • Surgery
  • Lung Volume Reduction Surgery (LVRS)
  • Lung Transplant, Bullectomy  
  • Others
  • Oxygen Therapy  

End User

  • Hospitals
  • Homecare Settings
  • Clinics
  • Others

Global Chronic Obstructive Pulmonary Disease Market Regional Analysis/Insights

The global chronic obstructive pulmonary disease market is analyzed, and market size insights and trends are provided by country, type, treatment type and end user, as referenced above.  

The countries covered in the global chronic obstructive pulmonary disease market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.    

North America dominates the global chronic obstructive pulmonary disease market because of the strong base of healthcare facilities, the strong presence of major players in the market, increasing cases of COPD conditions and rising number of research activities in this region.     

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global chronic obstructive pulmonary disease market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global chronic obstructive pulmonary disease market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the chronic obstructive pulmonary disease market. The data is available for the historic period 2015-2020.     

Competitive Landscape and Global Chronic Obstructive Pulmonary Disease Market Share Analysis

The global chronic obstructive pulmonary disease market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.   

Some of the major players operating in the global chronic obstructive pulmonary disease market are:  

  • AstraZeneca (UK)
  • Boehringer Ingelheim International GmbH (Germany)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • CHIESI Farmaceutici SpA (Italy)
  • Sunovion Pharmaceuticals Inc (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Mylan N.V. (US)
  • Orion Corporation (Finland)
  • Merck & Co., Inc (US)
  • Grifols, S.A. (Spain)
  • Abbott (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Vectura Group plc (UK)
  • Pfizer Inc (US)
  • Alkermes (Ireland)
  • Almirall, S.A (Spain)
  • Genentech, Inc (US)
  • Biogen (US)
  • Astellas Pharma Inc. (Japan)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The chronic obstructive pulmonary disease market size is known to be worth USD 30.4 billion by 2030.
The chronic obstructive pulmonary disease market growth rate is 4.4% by 2030.
Type, treatment type, and end-user are the factors on which the chronic obstructive pulmonary disease market research is based.
GlaxoSmithKline Pharmaceuticals launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients & Teva announced FDA approval of ArmonAir Digihaler inhalation powder, an inhaled corticosteroid (ICS) delivered via Teva’s Digihaler™ device containing built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma are the latest developments in the chronic obstructive pulmonary disease market.
Increasing awareness and diagnosis & rise in the cases of copd are the growth drivers of the chronic obstructive pulmonary disease market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials